secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001104659-26-002750
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics announces investor presentations with updated corporate deck
------------------------------------------------------------------------------

- Company to present to investors over next several weeks; updated deck filed as Exhibit 99.1.
- Presentation titled 'Unique Oncolytic Virus Therapies for Multiple Solid Tumors' dated Jan 2026.
- CEO Steven Shallcross signed the filing; stock trades on NYSE American under TOVX.
- No specific financial or clinical data disclosed in the filing or exhibit text provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465926002750/0001104659-26-002750-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465926002750/tm262896d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002750

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer